Jobs / United States / Iovance Biotherapeutics INC

Iovance Biotherapeutics INC

Vice President, Research

Tampa, FL/ ICTC Philadelphia, PA / Hybrid Posted 2 days ago

Apply on employer site ↗ Tailor my CV first Source: Company careers site

Optional: we can tailor a CV and cover letter for this job from your real experience first (the first one is free).

Sponsorship verdict

Sponsorship possible

One solid signal, not two. Worth applying, and worth asking about sponsorship early.

  • Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Apr 2026) — the step every H-1B hire needs first.
  • The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
  • No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
  • Confirmed live todayWhen a source last listed this job as open.
Details and sources
Employer is on a government sponsor record
The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Apr 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
No salary bar for this route
H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.

US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).

A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.

About the role

About   Iovance Biotherapeutics, Inc.   Iovance Biotherapeutics , Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The  Iovance TIL platform  spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit  www.iovance.com . Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on  www.iovance.com . Overview The Vice President, Research will provide strategic and operational leadership across translational sciences, platform research, bioinformatics, and preclinical research activities supporting Iovance’s industry-leading tumor infiltrating lymphocyte (TIL) therapy platform and next-generation cellular immunotherapy pipeline. As the leader in commercializing the first FDA-approved TIL therapy, Amtagvi®, Iovance is pioneering innovative approaches to harness the immune system to treat solid tumors. Reporting to the Executive Vice President, Translational Medicine & Research, the VP, Research will play a critical role in advancing discovery and translational research programs, driving IND-enabling activities, and expanding the scientific foundation of Iovance’s cellular therapy platforms. The ideal candidate is an accomplished biotechnology leader with deep expertise in cell therapy, tumor immunology, translational medicine, and preclinical drug development. This individual will oversee multidisciplinary scientific teams spanning translational sciences, bioinformatics, platform research, and preclinical development, while partnering cross-functionally to accelerate innovative therapies into the clinic. Essential Functions and Responsibilities Scientific & Strategic Leadership • Lead and oversee translational sciences, platform research, bioinformatics, and preclinical research functions supporting Iovance’s TIL therapy and immuno-oncology pipeline. • Partner closely with the EVP, Translational Medicine & Research to define and execute research strategy aligned with corporate and pipeline objectives. • Advance next-generation cellular therapy approaches through innovation in tumor immunology, immune cell engineering, and translational biology. • Drive scientific rigor, innovation, and operational excellence across research and translational programs. Translational Sciences & IND-Enabling Research • Lead translational medicine strategies supporting biomarker discovery, patient selection, mechanism-of-action studies, and translational endpoints. • Oversee IND-enabling research activities, including preclinical pharmacology, proof-of-concept studies, and translational data packages supporting regulatory submissions. • Ensure effective integration of translational findings into clinical development strategies and decisio

Apply on employer site ↗